


Annual GALIEN FORUM


 Novel Approaches to
Combatting Opioid Addiction

 Cancer in a Time
of Disruption


Making Medicines Affordable


 What's Holding Back the Technology
Revolution in Clinical Trials?

 The Promise of
Gene Therapy

 The Gut Microbiome:
Opportunities and Challenges

1

 A LEADING
GLOBAL HEALTHCARE &
LIFE SCIENCE EVENT

2018

New York City, October 25, 2018

Alexandria Center™ for Life Science

 450 East 29th Street, 2nd Floor, between 1st Avenue and the East River, NYC


IN THE PROGRAM:

07:00 am – 07:30 am Registration and coffee

 07:30 am – 07:45 am **Welcome**

 07:45 am – 08:50 am **Novel Approaches to Combatting Opioid Addiction**
Robert Langer, M.D., Ph.D., Chair, David Koch Institute Professor, Massachusetts Institute of Technology
Patrice A. Harris, M.D., President-elect, American Medical Association
Michael Heffernan, Chairman, Collegium Pharmaceutical
Corey McCann, M.D., Ph.D., President and CEO, Pear Therapeutics

 08:50 am – 09:55 am **Cancer in a Time of Disruption**
Joel S. Marcus, Co-chair, Executive Chairman & Founder of Alexandria Real Estate Equities, Inc./ Alexandria Venture Investments; Co-Founder, Alexandria Summit
Lynne Zydowsky, Ph.D., Co-chair, President and Co-Founder of the Alexandria Summit and Chief Science Officer of Alexandria Real Estate Equities, Inc./ Alexandria Venture Investments
Alexis Borisy, Partner, Third Rock Ventures
George D. Demetri, M.D., Senior Vice President for Experimental Therapeutics, Dana-Farber Cancer Institute; Professor of Medicine & Director, Ludwig Center, Harvard Medical School; Associate Director for Clinical Sciences, Dana-Farber/Harvard Cancer Center
Lee N. Newcomer, M.D., Principal, Lee Newcomer Consulting LLC; Former Senior Vice President, Oncology and Genetics, UnitedHealthcare
David Schenkein, M.D., Chief Executive Officer, Agios Pharmaceuticals

Sponsored by:


 ALEXANDRIA.
Building the Future of Life-Changing Innovation

09:55 am – 10:15 am Coffee Break

 10:15 am – 11:20 am **Making Medicines Affordable**
Michael Rosenblatt, M.D., Chair, Chief Medical Officer, Flagship Pioneering at Dallas
Sir Andrew Dillon, Chief Executive, National Institute for Health and Care Excellence (NICE), UK
John Furey, Chief Operating Officer, Spark Therapeutics Inc.
Scott Howell, M.D., M.B.A., Vice-President and Head, US Market Access, Novartis Pharmaceuticals Inc.
Gary Pisano, Ph.D., Harry E. Figgie Professor of Business Administration, Harvard Business School
Kent Rogers, M.B.A., Senior Vice President, Industry Relations, UnitedHealth Group Inc.

 11:20 am – 12:00 pm **Keynote: Anna K. Abram, Deputy Commissioner for Policy, Planning, Legislation and Analysis. FDA**
Moderator: Sue Desmond-Hellmann, M.D., M.Ph., Chief Executive Officer Bill & Melinda Gates Foundation, Prix Galien USA Committee Chair

12:00 pm – 01:15 pm Lunch Break

 01:15 pm – 02:20 pm **What's Holding Back the Technology Revolution in Clinical Trials?**
Mauro Ferrari, Ph.D., Chair, Ernest Cockrell Jr. Presidential Distinguished Chair President and CEO, Houston Methodist Research Institute Executive Vice President, Houston Methodist Hospital System
Marc M. Boutin, JD, CEO at the National Health Council
Paula Brown Stafford, M.Ph., Chief Development Officer, Novan, Inc. & Adjunct Professor of Public Health Leadership - University of North Carolina at Chapel Hill, Co-Founder of Habergeon LLC
Gerard Nahum, M.D., Vice President, Global Clinical Development for Medical Devices & eHealth, Bayer Pharmaceuticals
Steve Rosenberg, Senior Vice President and General Manager of Oracle Health Sciences

Sponsored by:



 02:20 – 03:25 pm **The Promise of Gene Therapy**
Mikael Dolsten, M.D., Ph.D., Chair, President, Worldwide Research and Development, Pfizer Inc.
Philip D. Gregory, Ph.D., Chief Scientific Officer, bluebird
Kathy High, President and head of Research and Development - Spark Therapeutics
Brian Kaspar, Ph.D., Scientific Founder and Chief Scientific Officer at AveXis, Inc.
Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research, FDA
Gaurav Shah, President and CEO, Rocket Pharmaceuticals, Inc.

 03:25 pm – 04:30 pm **The Gut Microbiome: Opportunities and Challenges**
Nancy Thornberry, Chair, CEO, Kallyope
Michael Fischbach, Ph.D., Associate Professor of Bioengineering, Stanford University
Dan R. Littman, M.D., Ph.D., Co-founder, Vedanta Biosciences
Sarkis K. Mazmanian, Ph.D., Louis & Nelly Soux Professor of Microbiology Division of Biology & Biological Engineering California Institute of Technology
Bernat Olle, Ph.D., Chief Executive Officer, Vedanta Biosciences

 04:30 pm – 04:40 pm **Conclusion**

 For more information,
please contact our offices

212 685 1592

forum@galienfoundation.org

Share:


[REGISTER NOW](#)